In the JournalsPerspective

Oral daclatasvir plus sofosbuvir highly effective in HCV patients

January 16, 2014
A once-daily oral regimen of daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients with hepatitis…
In the Journals

HCV prevalence among Hispanics varies by group

January 15, 2014
New findings indicate that the prevalence of hepatitis C varies widely among Hispanic/Latino groups in the United States. In Puerto Rican men, for…
Industry News

Oral combination therapy for HCV delivers 85% SVR4

January 14, 2014
An all-oral, direct-acting antiviral combination therapy of samatasvir and simeprevir plus ribavirin resulted in up to 85% of patients achieving…
Industry News

VX-135/daclatasvir therapy yields positive SVR4 results in HCV patients

January 13, 2014
A study of Vertex Pharmaceuticals’ VX-135 in combination with daclatasvir resulted in 83% of patients achieving sustained virologic response at…
In the Journals

Widespread access to new HCV antivirals feasible within 15 years

January 10, 2014
Large-scale manufacturing of direct-acting antivirals for hepatitis C is possible within the next 15 years, with a minimum target price of $100 to…
Industry News

Daclatasvir OK’d for accelerated review as HCV treatment by European Medicines Agency

January 9, 2014
The European Medicines Agency has validated the marketing authorization application by Bristol-Myers Squibb for daclatasvir, marking the beginning of…
In the Journals

Support program improved HCV treatment results, cost-effectiveness

January 7, 2014
A multidisciplinary support program increased the likelihood that patients would reach end of treatment and achieve sustained virologic response when…
In the Journals

Hepatitis took decades off expected life span

January 3, 2014
Hepatitis was listed as a cause of death for more than 18,000 people in 2010 in the United States, and the deaths occurred 22 to 23 years earlier…
In the Journals

Anti-TB drug hepatotoxicity increased in those with HCV

January 2, 2014
Patients coinfected with hepatitis C and tuberculosis are more likely to experience drug-induced hepatotoxicity related to first-line tuberculosis…

IDUs decreased drug use after HCV seroconversion

December 30, 2013
Injection drug users who test positive for hepatitis C were more likely to decrease their drug use, according to researchers from the University of…